NGL Fine-Chem Ltd. (NGLFINE) Share Price Rises 10.67% as Small Cap Stock Enters Top Gainers Today
- August 18, 2026
- Posted by: Harsh Piplani
- Category: News
NGL Fine-Chem Ltd. Share Price rose to Rs 3,242.20, up 10.67% today, taking the small-cap healthcare stock with a market capitalisation of Rs 2,139.20 crore into focus.
NGL Fine-Chem Ltd. Share Price moved sharply higher to Rs 3,242.20 on 18 August 2026, up Rs 312.55 or 10.67% from the previous close of Rs 2,929.65, lifting the company’s market capitalisation to Rs 2,139.20 crore. In Stock Market Today and Share Market Today screens, that makes the counter one of the notable top gainers and a stock firmly in the day’s Market News cycle.
The verified data confirms the price rise, the scale of the move and the trading range, but it does not establish a company-specific catalyst behind today’s move. That matters because NGL Fine-Chem Ltd. Stock News is being driven by the price event itself rather than a disclosed trigger in the supplied dataset. For investors tracking NGL Fine-Chem Ltd. Share Price Today, the key facts are that the stock opened lower than its current level, travelled from an intraday low of Rs 2,885.90 to a high of Rs 3,259.85, and held near the upper end of that range by the time of the event.
From a financial-analysis perspective, the market is also watching a business that trades at a P/E ratio of 31.64 and a P/B ratio of 5.21, while posting ROE of 27.90% and ROCE of 33.91%. Those profitability numbers stand out within its industry dataset. The next things investors may monitor are whether price action remains supported by volume, how the valuation compares with sector benchmarks and peers, and whether this NGL Fine-Chem Ltd. Share Price rise develops into a broader re-rating or remains a single-session move. Throughout this analysis, Univest focuses only on the verified numbers supplied for this stock update.
NGL Fine-Chem Ltd. (NGLFINE) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 3,242.2 |
| Previous Close | Rs 2,929.65 |
| Today's Change | +Rs 312.55 (+10.67%) |
| Day Open | Rs 2,885.9 |
| Day High | Rs 3,259.85 |
| Day Low | Rs 2,885.9 |
| Current Volume (BSE) | 1,851 |
| BSE Traded Volume | 1,851 |
| NSE Traded Volume | 52,993 |
| Combined NSE + BSE Volume | 54,844 |
| Turnover | Rs 0.6 crore |
| Market Capitalisation | Rs 2,139.2 crore |
| Market Cap Category | Small Cap |
NGL Fine-Chem Ltd. (NGLFINE) traded at Rs 3,242.2. versus the previous close of Rs 2,929.65, a rise of 10.67%. The stock opened at Rs 2,885.9, reached Rs 3,259.85, touched Rs 2,885.9. Reported volume was 1,851.
NGL Fine-Chem Ltd. (NGLFINE) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,139.2 crore |
| P/E Ratio | 31.64x |
| P/B Ratio | 5.21x |
| ROE | 27.9% |
| ROCE | 33.91% |
| EPS | Rs 92.59 |
| Dividend Yield | 0.06% |
NGL Fine-Chem Ltd. was valued at a P/E ratio of 31.64x, a P/B ratio of 5.21x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 27.9% and ROCE of 33.91%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 92.59, dividend yield of 0.06%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
NGL Fine-Chem Ltd. Fundamental Analysis shows a company that combines small-cap size with relatively strong profitability metrics. The stock is not being valued like a distressed business: its P/E, P/B and return ratios indicate that the market is already assigning value to earnings quality and capital efficiency, even after today’s price rise.
At a market capitalisation of Rs 2,139.20 crore, NGL Fine-Chem Ltd. remains a small-cap company, which describes size rather than quality. Its P/E ratio of 31.64 means the stock trades at 31.64 times earnings, while the P/B ratio of 5.21 shows the market values the company at 5.21 times its book value. The earnings per share, or EPS, stands at 92.59, a direct measure of earnings attributable to each share. The dividend yield is 0.06, which indicates a very modest historical payout relative to the current stock price and suggests the investment case in current trading is not centered on income.
Profitability is where the supplied numbers appear stronger. ROE is 27.90%, showing the company generates 27.90% return on shareholder equity, while ROCE is 33.91%, indicating strong returns on capital employed. These are important because high return ratios often help explain why investors continue to monitor a stock even after a swift NGL Fine-Chem Ltd. Share Price Today move. In simple terms, the company is not only profitable on paper but also relatively efficient in generating returns from the capital base it uses.
Valuation, however, still needs context. A P/E of 31.64 is above the industry median of 26.24 but below the industry average of 39.98 in the supplied same-industry benchmark. Likewise, the P/B ratio of 5.21 sits above both the benchmark median of 1.82 and the benchmark average of 2.49. That suggests the stock’s valuation is not cheap on book value terms relative to the broader Pharmaceuticals & Drugs set, even though the market may be rewarding stronger profitability.
For investors reading NGL Fine-Chem Ltd. Stock Analysis, the combination to watch is clear: a market cap of Rs 2,139.20 crore, EPS of 92.59, P/E of 31.64, P/B of 5.21, ROE of 27.90%, ROCE of 33.91% and dividend yield of 0.06. Those numbers provide a meaningful framework for assessing whether today’s NGL Fine-Chem Ltd. Share Price move is drawing attention because of underlying financial quality as well as pure price action. Univest therefore sees valuation and efficiency as central to the discussion, even without a verified company-specific trigger in today’s data.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 31.64x |
| Benchmark Median P/E | 26.24x |
| Benchmark Average P/E | 39.98x |
| Benchmark P/E Range | 2.96x to 359.13x |
| Company P/B Ratio | 5.21x |
| Benchmark Median P/B | 1.82x |
| Company ROE | 27.9% |
| Benchmark Median ROE | 10.49% |
| Company ROCE | 33.91% |
| Benchmark Median ROCE | 12.97% |
| Company Market Capitalisation | Rs 2,139.2 crore |
| Benchmark Median Market Cap | Rs 142.37 crore |
NGL Fine-Chem Ltd. (NGLFINE) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
NGL Fine-Chem Ltd. (NGLFINE) has a P/E ratio of 31.64x, which is above the benchmark median of 26.24x, a difference of +20.58%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
NGL Fine-Chem Ltd. (NGLFINE) has a ROE of 27.9%, which is above the benchmark median of 10.49%, a difference of +165.97%. NGL Fine-Chem Ltd. (NGLFINE) has a ROCE of 33.91%, which is above the benchmark median of 12.97%, a difference of +161.45%.
Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.
NGL Fine-Chem Ltd. operates in Healthcare and specifically in Pharmaceuticals & Drugs, so the most relevant benchmark is the supplied same-industry comparison set. On that basis, the stock trades at a valuation premium to some benchmark measures, but its profitability metrics stand well above the median and average industry levels.
The sector snapshot covers 136 companies in the same industry benchmark. Within that universe, NGL Fine-Chem Ltd. Share Price is being valued on a company P/E of 31.64. That compares with a benchmark median P/E of 26.24, an average P/E of 39.98, a minimum of 2.96 and a maximum of 359.13, based on 105 companies with P/E data. This places the company above the median but below the average, which usually suggests the stock is not at the extreme end of industry valuation even after today’s share price gain.
On price-to-book, the company’s P/B of 5.21 is meaningfully above the benchmark median of 1.82 and the benchmark average of 2.49, across 135 companies. The industry’s P/B range runs from -11.02 to 16.76, showing wide dispersion in balance-sheet valuation across the space. Profitability is where the picture turns more favorable for NGL Fine-Chem Ltd. Fundamental Analysis. Its ROE of 27.90% exceeds the benchmark median ROE of 10.49% and the average of 8.10%. Its ROCE of 33.91% also stands well above the median ROCE of 12.97% and average ROCE of 15.53%.
Industry size context is also useful. The benchmark market capitalisation dataset covers 136 companies, with a median of Rs 142.37 crore, an average of Rs 492.43 crore, a minimum of Rs 6.06 crore and a maximum of Rs 2,985.15 crore. Against that backdrop, NGL Fine-Chem Ltd. at Rs 2,139.20 crore sits far above the industry median and average, though below the top end of the supplied group. For readers following NGL Fine-Chem Ltd. Share Price News, that means today’s move occurred in a segment where the company is already one of the larger names in its industry sample. Univest reads this as a useful sign that the stock is not a very small fringe counter inside its peer set.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,985.15 | 170.32 | 0.42 | -2.89 | -0.26 |
| Beta Drugs Ltd. | BETA | 2,827.67 | 65.02 | 10.29 | 18.65 | 22.17 |
| Hikal Ltd. | HIKAL | 2,686.72 | 0 | 2.2 | 15.22 | 16.15 |
| Ind-Swift Laboratories Ltd. | INDSWFTLAB | 2,645.37 | 47.53 | 1.82 | -0.78 | 8.31 |
| Fredun Pharmaceuticals Ltd. | FREDUN | 2,559.68 | 54.85 | 8.19 | 11.42 | 13.15 |
NGL Fine-Chem Ltd. (NGLFINE) has a P/E ratio of 31.64x compared with the displayed peer median of 54.85x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 27.9% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at 33.91% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. NGL Fine-Chem Ltd. (NGLFINE) has a market capitalisation of Rs 2,139.2 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
NGL Fine-Chem Ltd. compares with a supplied peer set that includes Dishman Carbogen Amcis Ltd., Beta Drugs Ltd., Hikal Ltd., Ind-Swift Laboratories Ltd., Fredun Pharmaceuticals Ltd., Solara Active Pharma Sciences Ltd., Sai Parenteral’s Ltd., Panacea Biotec Ltd. and Venus Remedies Ltd. Across this group, the company’s valuation sits in the middle rather than at an extreme, while its return ratios compare favourably with most names listed in the dataset.
On market capitalisation, NGL Fine-Chem stands at Rs 2,139.20 crore, below Dishman Carbogen Amcis at Rs 2,985.15 crore, Beta Drugs at Rs 2,827.67 crore, Hikal at Rs 2,686.72 crore, Ind-Swift Laboratories at Rs 2,645.37 crore, Fredun Pharmaceuticals at Rs 2,559.68 crore, Solara Active Pharma Sciences at Rs 2,465.73 crore, Sai Parenteral’s at Rs 2,438.25 crore, Panacea Biotec at Rs 2,429.20 crore and Venus Remedies at Rs 2,388.41 crore. So in this specific peer basket, it is smaller than all named peers by market cap.
On valuation, its P/E of 31.64 is lower than Dishman Carbogen Amcis at 170.32, Beta Drugs at 65.02, Ind-Swift Laboratories at 47.53, Fredun Pharmaceuticals at 54.85 and Sai Parenteral’s at 170.53, but above Venus Remedies at 20.48. Several peers in the supplied set do not have P/E values shown, so the clearest takeaway is that NGL Fine-Chem trades below many high-multiple peers but above at least one lower-multiple name.
Return metrics are particularly important in this NGL Fine-Chem Ltd. Stock Analysis. ROE of 27.90% is above Beta Drugs at 18.65%, Hikal at 15.22%, Fredun Pharmaceuticals at 11.42%, Solara at 17.23%, Sai Parenteral’s at 13.90%, Panacea Biotec at 0 and Venus Remedies at 9.85%, and it is far above Dishman Carbogen Amcis at -2.89% and Ind-Swift Laboratories at -0.78%. ROCE of 33.91% also tops Beta Drugs at 22.17%, Hikal at 16.15%, Ind-Swift at 8.31%, Fredun at 13.15%, Solara at 15.34%, Sai Parenteral’s at 12.97%, Panacea Biotec at 5.36%, Venus Remedies at 7.89% and Dishman Carbogen Amcis at -0.26%.
That combination suggests the market may be pricing NGL Fine-Chem Ltd. Share Price at a premium to weaker-quality peers because its profitability metrics are materially stronger, even though the stock is not the largest company in the comparison group. Univest therefore sees the peer picture as balanced: valuation is not the cheapest, but return ratios are among the best in the supplied pack.
Why Investors Are Watching NGL Fine-Chem Ltd.
NGL Fine-Chem Ltd. Share Price is attracting attention because today’s move combines a double-digit gain with a close-to-high trading position, a small-cap classification, and profitability metrics that compare well against the broader Pharmaceuticals & Drugs benchmark. Even without a verified catalyst in the supplied data, that mix is enough to keep the stock on intraday and research watchlists.
- Verified price action: the stock rose Rs 312.55, or 10.67%, from Rs 2,929.65 to Rs 3,242.20.
- Intraday structure: it opened at Rs 2,885.90, touched Rs 3,259.85 and remained near the high.
- Trading activity: total volume reached 54,844 shares, including 1,851 on BSE and 52,993 on NSE, with turnover of Rs 0.60 crore on the reported exchange.
- Fundamental context: P/E is 31.64, P/B is 5.21, ROE is 27.90%, ROCE is 33.91%, EPS is 92.59 and dividend yield is 0.06.
- Sector positioning: ROE and ROCE both stand above industry median and average levels in the supplied 136-company benchmark.
The main things to monitor next are whether NGL Fine-Chem Ltd. Share Price can hold a meaningful part of today’s gains, whether market attention remains supported by active trading, and how investors continue to weigh the company’s stronger profitability against its above-median valuation multiples. Univest would also keep the stock in focus because today’s rise has pushed it into the conversation around Market Movers and Stocks Rising Today within the healthcare space.
About NGL Fine-Chem Ltd.
NGL Fine-Chem Ltd. belongs to the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. In the absence of additional business-segment disclosures in the supplied dataset, the most factual way to understand the company is through its industry placement and financial profile relative to listed peers.
The Pharmaceuticals & Drugs space in the supplied benchmark includes 136 companies and spans a wide size range, from Rs 6.06 crore to Rs 2,985.15 crore in market capitalisation. At Rs 2,139.20 crore, NGL Fine-Chem sits near the larger end of that sample, which is relevant for investors tracking NGL Fine-Chem Ltd. Latest News and company context. The company’s reported profitability ratios of 27.90% ROE and 33.91% ROCE place it comfortably above many peers in the same industry set, while its P/E ratio of 31.64 and P/B ratio of 5.21 show that the market values the business above benchmark medians.
For practical purposes, this means the stock currently stands out more for the combination of size, valuation and return profile than for any disclosed event-specific narrative in the supplied data. That is why NGL Fine-Chem Ltd. Company News today is dominated by the share price move itself. Investors using Univest to follow the stock are likely to view it as a healthcare counter where profitability metrics have become central to the market conversation alongside today’s sharp price rise.
Track NGL Fine-Chem Ltd. Share Price on Univest
Use NGL Fine-Chem Ltd. (NGLFINE) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.
Investors tracking NGL Fine-Chem Ltd. Share Price can use Univest to follow live share price moves, daily stock performance, valuation ratios and broader market context in one place. A focused stock page helps users monitor NGL Fine-Chem Ltd. Share Price Today, 52-week levels, market capitalisation, technical indicators when available, and key metrics such as P/E, P/B, ROE, ROCE, EPS and dividend yield.
Univest also helps users compare the stock with listed peers, review sector and industry benchmarks, and monitor shareholding pattern data when available. For readers following NGL Fine-Chem Ltd. Stock News, NGL Fine-Chem Ltd. Share News and NGL Fine-Chem Ltd. Share Price Live developments, that kind of structured view is useful for separating a one-day price rise from a broader valuation and business-quality discussion.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is NGL Fine-Chem Ltd. Share Price in focus today?
Ans. NGL Fine-Chem Ltd. Share Price is in focus because the stock rose 10.67% to Rs 3,242.20 from the previous close of Rs 2,929.65. That double-digit gain placed the small-cap healthcare stock among today’s notable top gainers.
What is NGL Fine-Chem Ltd. Share Price Today?
Ans. NGL Fine-Chem Ltd. Share Price Today was Rs 3,242.20 at the time of this update. The stock was up Rs 312.55 on the day, after trading between Rs 2,885.90 and Rs 3,259.85 in the current session.
How much did NGL Fine-Chem Ltd. stock rise today?
Ans. The stock rose by Rs 312.55, which equals a 10.67% gain over the previous close of Rs 2,929.65. The move is significant enough to make the counter one of the day’s market movers in the small-cap segment.
What does today’s intraday range show for NGL Fine-Chem Ltd.?
Ans. The stock opened at Rs 2,885.90, which was also the day’s low, and climbed to Rs 3,259.85 before trading at Rs 3,242.20. That pattern shows strong recovery from the open and retention of most intraday gains.
What is the market capitalisation of NGL Fine-Chem Ltd.?
Ans. NGL Fine-Chem Ltd. has a market capitalisation of Rs 2,139.20 crore in the supplied data. That places it in the Small Cap category and makes today’s 10.67% share price gain especially notable in event terms.
How active was trading in NGL Fine-Chem Ltd. today?
Ans. Total traded volume was 54,844 shares, with 1,851 shares on BSE and 52,993 shares on NSE. The reported turnover on the specified exchange was Rs 0.60 crore, showing active participation during today’s price rise.
What do the valuation ratios of NGL Fine-Chem Ltd. indicate?
Ans. The stock trades at a P/E ratio of 31.64 and a P/B ratio of 5.21. Its P/E is above the industry median of 26.24 but below the industry average of 39.98 in the supplied benchmark set.
How profitable is NGL Fine-Chem Ltd. based on supplied data?
Ans. Profitability metrics are strong in the supplied dataset, with ROE at 27.90% and ROCE at 33.91%. Both ratios are above the industry median and average figures, which helps explain sustained investor attention despite higher valuation multiples.
What are the EPS and dividend yield of NGL Fine-Chem Ltd.?
Ans. NGL Fine-Chem Ltd. has an EPS of 92.59 and a dividend yield of 0.06 in the supplied data. EPS reflects earnings per share, while the dividend yield points to a relatively modest historical payout level.
How does NGL Fine-Chem Ltd. compare with peers?
Ans. NGL Fine-Chem Ltd. has lower market capitalisation than the supplied peer names, but its ROE of 27.90% and ROCE of 33.91% are stronger than most peers listed in the comparison set. Its P/E of 31.64 is mid-range.
